# INCORPORATED

## LLOYD, Inc.

## SAFETY DATA SHEET

THYRO-TABS® CANINE Revision 01 Revision Date: 17 June 2015

1. <u>IDENTIFICATION</u>

**Product Name**: Thyro-Tabs<sup>®</sup> Canine

**Synonyms**: Levothyroxine sodium tablets, USP

Company: LLOYD, Inc.

604 West Thomas Avenue

P.O. Box 130

Shenandoah, IA 51601-0130

**USA** 

(712) 246-4000

**Emergency Contact:** National Capital Poison Center

(800) 222-1222

Recommended Use: For use in dogs for correction of conditions associated with low

circulating thyroid hormone (hypothyroidism).

#### 2. HAZARDS IDENTIFICATION

#### WARNING



**EYE**: This product is not expected to irritate the eyes.

**SKIN CONTACT**: This product is not expected to irritate the skin.

POLYVINYLPYRROLIDONE: May possibly cause skin irritation or dermatitis in some individuals upon prolonged contact. Oral LD50 (rat): >100 g/kg

**INGESTION**: This has not been evaluated.

**INHALATION**: Inhalation exposure under normal conditions of use is not likely to cause adverse effects. Generation of dust or prolonged excessive exposure to dust should be avoided to prevent adverse health effects.

**SIGNS AND SYMPTOMS OF EXPOSURE**: Levothyroxine Sodium: Effects of overexposure include nervousness, sweating, hyperhidrosis, insomnia, tachycardia, blood pressure variation, and loss of weight after ingestion.

## 3. <u>INFORMATION ON INGREDIENTS</u>

(% w/w), unless otherwise noted

|                      |           |               | EXPOSURE LIMITS, ppm |                 |
|----------------------|-----------|---------------|----------------------|-----------------|
|                      |           |               | OSHA                 | ACGIH           |
| COMPONENT            | CAS#      | %             | PEL                  | TLV (mg/m³)     |
| Polyvinylpyrrolidone | 9003-39-8 | 1.8           | TWA: 15 (total)      | TWA: 10 (total) |
|                      |           |               | 5 (respirable)       | 5 (respirable)  |
| Levothyroxine Sodium | 55-03-8   | 0.086 - 0.86* | None Established     |                 |

Revision Date: 17 June 2015

This document is prepared pursuant to the OSHA Hazard Communication Standard (29 CFR 1910.1200). Only those ingredients composing  $\geq$ 1% ( $\geq$ 0.1% for carcinogens or suspect carcinogens) of the formula (w/w) and which have hazards identified are listed. The exposure limits listed for polyvinylpyrrolidone are for nuisance dusts and not applicable in the solid dosage form.

#### 4. FIRST AID MEASURES

**EYES**: Immediately flush eyes with copious amounts of running water for 15 minutes.

**SKIN**: Wash with soap and water.

**INGESTION: SEEK MEDICAL ATTENTION IMMEDIATELY**. Induce vomiting and follow up with symptomatic and supportive treatment.

**INHALATION**: If a person has been exposed to excessive quantities of dust due to mishaps, move the person to fresh air. Give artificial respiration if not breathing.

SEEK MEDICAL ATTENTION IMMEDIATELY IF EXCESSIVE EXPOSURE OCCURS.

### 5. <u>FIREFIGHTING MEASURES</u>

This has not been evaluated.

**Extinguishing media**: Water fog, alcohol foam, CO<sub>2</sub>, dry chemical.

#### 6. ACCIDENTAL RELEASE MEASURES

**Action to take for spills/leaks**: Sweep up and dispose of in DOT-approved waste containers. Keep out of sewers, storm drains, surface waters and soil.

## 7. HANDLING AND STORAGE

**Special precautions to be taken in handling and storage**: Exercise reasonable care and caution.

<sup>\*</sup>This product is available in potencies of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 and 1.0 mg levothyroxine sodium per tablet.

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

There is no OSHA PEL or ACGIH TLV for this product. Under normal conditions of use, no special handling precautions are required in areas with adequate ventilation. However, under conditions of prolonged exposure in which quantities of dust are generated, mechanical ventilation, safety glasses with side shields, gloves and a NIOSH approved dust respirator are recommended.

Revision Date: 17 June 2015

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance**: Color-coded and potency-embossed scored caplet-shaped tablet; 0.1 mg - yellow; 0.2 mg - pink; 0.3 mg - green; 0.4 mg - maroon; 0.5 mg - white; 0.6 mg - purple; 0.7 mg - orange; 0.8 mg - blue; and 1.0 mg - tan.

Other physical data have not been determined.

## 10. STABILITY AND REACTIVITY

This has not been evaluated.

The product is expected to be stable under normal storage conditions; avoid strong oxidizers. Levothyroxine sodium produces highly toxic iodine vapors as hazardous decomposition products.

#### 11. TOXICOLOGICAL INFORMATION

N/A

#### 12. <u>ECOLOGICAL INFORMATION</u>

**Action to take for spills/leaks**: Sweep up and dispose of in DOT-approved waste containers. Keep out of sewers, storm drains, surface waters and soil.

#### 13. DISPOSAL CONSIDERATIONS

Dispose of contaminated product and materials used in cleaning up spills or leaks in a manner approved for this material. Consult appropriate federal, state and local regulatory agencies to ascertain proper disposal procedures.

#### 14. TRANSPORT INFORMATION

No special transportation required

Revision Date: 17 June 2015

## 15. REGULATORY INFORMATION

## (Not meant to be all-inclusive--selected regulations represented.)

NOTICE: The information herein is presented in good faith and believed to be accurate as of the effective date shown above. However, no warranty, express or implied, is given. Regulatory requirements are subject to change and may differ from one location to another; it is the buyer's responsibility to ensure that its activities comply with federal, state or provincial, and local laws. The following specific information is made for the purpose of complying with numerous federal, state or provincial, and local laws and regulations. See SDS for health and safety information.

**U.S. REGULATIONS:** SARA HAZARD CATEGORY: This product has been reviewed according to the federal EPA "Hazard Categories" promulgated under Sections 311 and 312 of the Superfund Amendment and Reauthorization Act of 1986 (SARA Title III) and is considered, under applicable definitions, to be exempt from reporting requirements. Nevertheless, potential reporters should check with their state emergency response commissions to determine if this product must be reported under applicable state requirements.

#### 16. OTHER INFORMATION

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.